Test Price
2,800 AED✅ Home Collection Available
FLNB Gene Atelosteogenesis Type 1 Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
Accuracy Guarantee
99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited NGS Processing with full gene coverage and deletion/duplication analysis, validated against DHA/MOHAP standards.
Premium Logistics
VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection – Available daily from 8 AM to 11 PM across all Emirates.
Clinical Guidance
Telephonic Post-Test Clinical Guidance by a DHA-licensed Consultant Medical Geneticist to interpret your FLNB variant report and its implications for your health and family.
Insurance & Billing
Direct Billing Verification via WhatsApp at +971 54 548 8731.
Executive Summary: This definitive NGS test identifies pathogenic variants in the FLNB gene causing Atelosteogenesis Type 1 (AO1), a severe skeletal dysplasia. Governed by Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, your genetic data is handled with utmost privacy and clinical rigor.
Test Overview & Methodology
The FLNB Gene Atelosteogenesis Type 1 Genetic Test screens the entire coding region of the filamin B gene using next-generation sequencing for single nucleotide variants, small indels, and copy number variations implicated in lethal skeletal dysplasia AO1. This test is indicated for neonatal diagnosis, carrier screening, and familial variant tracking—crucial for definitive clinical management and genetic counseling.
| Test Parameter | Our Test (DHA-MOHAP Lab) | Closest Alternative (Conventional Sanger) |
|---|---|---|
| Precision | >99.9% analytical sensitivity, full exon coverage | ~98% for point mutations, limited CNV detection |
| Methodology | NGS with bioinformatic DHA-validated pipeline | Sanger sequencing of selected exons |
| Turnaround Time | 3–4 Weeks (expedited options) | 6–8 Weeks |
| Regulatory Compliance | ISO 9001:2015, MOHAP/DHA genetic testing license | Varies; often lacks UAE genetic law adherence |
Physician Insight & Safety Protocols
“As a DHA-licensed Consultant in Medical Genetics, I emphasize that a molecular diagnosis of Atelosteogenesis Type 1 carries profound clinical implications. The FLNB NGS test result must be correlated with complete radiographic skeletal surveys and the full clinical phenotype; it is not a standalone predictor of severity. A negative result does not exclude other skeletal dysplasias, and any variant of uncertain significance warrants comprehensive family segregation studies. Your referring physician will integrate this precise genetic data with your child’s complete health picture for optimal management.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA ID: 9294403
Clinical Advisory & Medication Safety
Clinical Advisory & Medication Safety
Do not discontinue any prescribed medication without consulting the managing physician.
- This genetic test is an adjunct to clinical care and is not a substitute for emergency medical intervention.
- All results must be interpreted within the context of the complete clinical picture by a qualified specialist.
- Patients and families should be offered referral to a clinical geneticist for comprehensive counseling regarding recurrence risks and prenatal options.
Exclusion Criteria & Emergency Indicators
Exclusion Criteria & Emergency Indicators
- Inability to provide a valid DNA sample (blood, FTA card, or extracted DNA) of sufficient quality and quantity for NGS library preparation.
- Unavailability of pre-test genetic counseling session, which is mandatory for informed consent.
- ER Red Flags: Neonatal respiratory distress, severe limb foreshortening, joint dislocations, or profound hypotonia demand immediate acute medical care irrespective of genetic testing status.
Patient FAQ & Clinical Guidance
1. What is the FLNB Gene Atelosteogenesis Type 1 NGS test, and how does it work?
This test utilizes next-generation sequencing technology to analyze the entire coding region of the FLNB gene. It detects DNA mutations responsible for Atelosteogenesis Type 1 (AO1), a severe skeletal disorder often identifiable in the prenatal or neonatal period. The result guides reproductive planning, prenatal diagnosis in future pregnancies, and neonatal management strategies.
2. Why choose this test over other genetic tests for skeletal dysplasia?
Our DHA-licensed molecular genetics laboratory offers high-depth, ISO-certified NGS with expert variant interpretation validated for Middle Eastern populations. Unlike standard skeletal dysplasia panels that may miss rare copy number changes in FLNB, this targeted single-gene assay provides the highest diagnostic yield and is considered the gold standard for confirming suspected AO1.
3. What is the turnaround time and sample collection process for the FLNB genetic test?
Results are delivered within 3–4 weeks after the laboratory receives the specimen. Suitable sample types include peripheral whole blood, extracted DNA, or a dried blood spot on an FTA card. Our temperature-controlled cold-chain home collection courier service is available daily from 8 AM to 11 PM. A mandatory pre-test genetic counseling session is scheduled prior to sample submission.
UAE Regulatory & Data Privacy Adherence
Your Data, Your Rights
Your genetic data is handled in strict compliance with:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – governing the collection, processing, and storage of your sensitive genetic information.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – ensuring secure handling of digital health records and telemedicine interactions.
- Federal Decree-Law No. 4 of 2016 on Medical Liability – guaranteeing your right to informed consent, safety, and clinical transparency throughout the diagnostic process.
Clinical & Logistical Metadata
| Test Name | FLNB Gene Atelosteogenesis Type 1 Genetic Test (NGS) |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood, Extracted DNA, or FTA Card |
| Methodology Used | Next-Generation Sequencing (NGS) with full gene coverage and CNV analysis |
| ICD-10-CM Code | Q77.3 (Atelosteogenesis) |
| LOINC Code | 21636-6 (Genetic analysis FLNB gene) |
| DHA Facility License & Address | DHA License 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians